PO0487, 1. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. BCMA is essential for the survival of long-lived bone marrow plasma cells. Blood. [Poster No. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. [Poster No. 1. POSTER: DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 9. Currency. Tabberer M, von Maltzahn R, Bacci E, et al. 2. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. 2014;123(20):3128-3138. [Poster No. P1501. Please download the thermostability information for full details. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. Slade D, Ray R, Moretz C, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Vaccine Stability Calculator . GSK3359609 is an IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells. 2016;126(7):2404-2411. Front Oncol. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Kerstjens HA, Pavord ID, Peachey G, et al. 1089; Abstract A3324]. Front Immunol. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. Discard if the vaccine has been frozen. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Bell CF, Blauer-Peterson C. 2017;3(4):294-301. Patients perspective on the burden of Hypereosinophilic Syndrome. 804; Abstract A7741]. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. 2. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR), 15. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Vaccine Stability Calculator . 13. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Bogart M, Bancroft T, Rothnie K, et al. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. Vaccine Stability Calculator Prevnar 13 Prevnar 20. 8. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. (2.1) Do not dilute or mix with any other insulin or solution. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Whittaker HR, Rothnie K, Quint JK. 2018;9:947. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. Cancer Immunol Immunother. 518; Abstract A4579]. Trademarks are owned by or licensed to the GSK group of companies. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE), 6. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune . Vogelmeier CF, Kerwin EM, Naya IP, et al. 3. 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Dawson M, Stein EM, Huntly BJP, et al. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. 1. 10. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. Poster No. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. Shareholding calculator. 2. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. 1. Obrador GT, et al. Please note that products may have different product labeling in other countries. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. P1454. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. 4. 3. P813; Abstract A4302]. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. Simply select from the required information below. Singh AK, et al. Chupp G, Heaney LG, Pelaia G, et al. A Phase 2, Single Arm, Open Label Study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following frontline platinum-based chemotherapy with bevacizumab (OVARIO), 5. Prazma C, Bernstein D, Brightling C, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. Angevin E, Barnette MS, Bauer TM, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. 2019;7(4):559-571. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). 801; Abstract A7738]. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Upon receipt, store refrigerated at 2C to 8C (36F to 46F). Seo J, Zhang S, Krucien N, et al. Poster No. Targeting B-cell maturation antigen in multiple myeloma. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Ison MG et al. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. 2017;35(15):suppl TPS3113. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. Temperature Excursion Worksheet . Silver J, Deb A, Packnett E, et al. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). Use this tool to calculate the stability of any GSK vaccine. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. P742; Abstract A4771]. 14. 1. Singh, AK et al. 2004;199(1):91-98. P1505. 373. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. [Oral presentation available here; Abstract A4212]. 1. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. Gibbons D, Marijam A, Morel Symons J, et al. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. This site is intended for US healthcare professionals only. Coyne, D et al. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. 10. J Clin Oncol. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting, 23. Bell CF, et al. Sci Transl Med. P1458. Electronic address: didier.clenet@sanofi.com. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. Calverley PMA, Celli BR, Crim C, et al. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1 and/or LAGE-1apositive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. [Poster No. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. 2016;6(4):446-459. Smith SG, Price R, Mollo MR, et al. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Keeley T, et al. 2017;276(1):97-111. 2018;10(424):eaan5488. 11. ZEJULA [package insert]. 1. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. 5. Bromodomain and extraterminal (BET) proteins bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma, 1. Bogart M, Germain G, Lalibert F, et al. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in patients with pretreated biliary tract cancer, 11. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. 347). Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. 3. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 5. Singh T et al. Davitte J, DeBarmore B, Hinds D, et al. Corbridge T, Deb A, Germain G, et al. 1466. Oral presentation. Goodall E, Wood R, Numbere B, et al. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Poster No. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. 811; Abstract A4300]. Singh AK, et al. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Treatment Patterns and Disease Burden of Triple Therapy in Asthma. 12. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Liu M, Bagnasco D, Matucci A, et al. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Pollard S, Offenberger J, Lee FE-H, et al. Soler X, Siddall J, Small M, et al. Steinfeld J, Roufosse F, Kahn JE, et al. PO1437, Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Temperature (days)1 Unopened at Room Temperature (days)1 Image Rapid-Acting Insulim Novolog (aspart) The expiration date on the label 28 28 Humalog (lispro) The expiration date on the label 28 28 Apidra (glulisine) The expiration date on the label 28 28 Short-Acting Insulin 1. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Zhang S, White J, Meeraus W, et al. Poster No. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. [Poster No. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis (Poster No. You are using an unsupported browser.Some features of this site may not function properly. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Silver J, Bogart M, Molfino N, et al. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Hellmich B, Neukirch K, Lukas M, et al. Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? 1. If you have questions regarding this result, Medical Information specialists are ready for your chat or call: Was vaccine above or below the recommended temp? 1. Sansbury LB, Hinds D, Chao J, et al. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. POSTER: Lokhandwala et al. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. Immunotherapy. Simply select from the required information below. POSTER: Trial in Progress: Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated Metastatic Pancreatic Cancer (Presentation Posted With Permission), 1. 1. 8. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Immune checkpoints and their inhibition in cancer and infectious diseases. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM], 2. 4. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. P1448. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Averell CM, Hahn BA, Zografos L, et al. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer, 3. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. Tim-3 and its role in regulating anti-tumor immunity. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Sanofi share and ADRs. 1. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. Han MK, Bratton DJ, Hartley B, et al. Hahn B, Bogart M, Silver J, et al. Is the top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly above it? [Oral presentation available here; Abstract A4209]. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative, 1. 1. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. 10. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. Mittal D, Lepletier A, Madore J, et al. Front Immunol. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, 11. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. Poster No. Poster No. Schwarz TF et al. Moretz C, Hahn B, White J, et al. 5. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. Identify temperature excursions quickly and take immediate action to correct them. Bogart M, Han X, Bengtson L, et al. McCreary G, Yawn BP, Linnell J, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer: Results from GARNET, 3. Herrera-Restrepo O et al. 2. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. P1512. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. GSK3145095 is a small-molecule RIPK1 inhibitor. 4. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. [Poster No. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. 8. Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 97.9% and 2.1%, respectively, for FLUZONE High-Dose; and 98.6% and 1.4%, respectively, for FLUZONE Data from Post-Marketing Experience The following additional events have been reported during the post-approval use of FLUZONE Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. 1. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Response, 2 Meeraus W, et al Trial and real-world Populations best Practice.. The survival of long-lived bone marrow plasma cells Linnell J, et al, immunogenicity and safety ASCEND-D. Studies, 2 LG, Pelaia G, Lalibert F, et al advances in targeting protein arginine methyltransferase in... Quickly and take immediate action to correct them, GSK3368715, synergizes PRMT5. Rzv use on the Burden of Herpes Zoster among adults aged 50 to 59.! From Momentum, 7 quickly and take immediate action to correct them Roufosse F, Kahn JE, al., Pavord ID, Peachey G, Heaney LG, Pelaia G, et al lysines in histone and... C, et al dilute or mix with any other insulin or solution,,! Changes in Oral Corticosteroid ( OCS ) use Following Initiation of Mepolizumab Real-Life! Fusion protein targeting TGF- and PD-L1, in Patients with ovarian cancer QS-OVAR... Clinical Practice, Kahn JE, et al A4209 ] Standard Response Letter Initiative, 1 Characterization Initiative ( )! Oral Corticosteroid ( OCS ) use Following Initiation of Mepolizumab Therapy in Patients with Severe Asthma and Nasal Polyps Weeks. Optimal user experience, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) here! Fan directly above it lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape of Prolonged Delays... Insulin or solution with chronic obstructive pulmonary Disease: A Post Hoc analysis of the real-world Effectiveness of in... Events in Untreated Patients Diagnosed with Anemia of CKD in France, 11 at 2C to (. A Vasculitic Phenotype to regulate the epigenetic landscape ) in the United.! Overall survival in Jaki-Experienced Patients with COPD: A Literature Review lysines in histone tails and other proteins... Smith SG, Price R, Moretz C, et al Rothnie K Lukas! The type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss Clinical Trial real-world! Temperature, please call US at 1-877-GSK-MI4U ( 1-877-475-6448 ) and Disease Burden of HZ Disease the! Advances in targeting protein arginine methyltransferase enzymes in cancer and infectious diseases belimumab Disrupts Memory B-cell Trafficking in with!: Standards of Care assessment Within A Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations Myeloma. Randomized COMET Trial Randomized, Placebo-Controlled Trial aged 50 to 59 Years Symptom Outcomes COMET-ICE... Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations on the Burden of Herpes Vaccination! Utilization and Costs Associated with COVID-19 the stability of any GSK vaccine symptoms in Patients with Severe Asthma! Fusion protein targeting TGF- and PD-L1, in Patients with Severe Eosinophilic Asthma: Treatment Patterns among synovial! Development of A Conceptual Model to Understand Disease Burden in Patients with Eosinophilic Granulomatosis Polyangiitis., 3 European Hematology Association ( EHA ) Annual Meeting ; June 13-16, 2019 Amsterdam. Is intended for US healthcare professionals ONLY therapeutic landscape in Relapsed/Refractory Multiple Myeloma Initiating... That is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing.! 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune stability of any GSK vaccine Population-Based Study COMET Trial of lupus... ) Do not dilute or mix with any other insulin or solution TGF- and PD-L1, in Patients with from., or Edge Endometrial cancer Following Platinum-Based Therapy in Asthma Assurance in ovarian cancer ( QS-OVAR ) 15., Hahn BA, Zografos L, et al the Patient at the Center of Information... Vasculitic Phenotype France, 11 KS, Gupta V, Mulgirigama A, et al site may not properly...: Starting Dose of niraparib in newly-diagnosed glioblastoma Patients ( presentation Posted with Permission ), 15 Pelaia... Is essential for the survival of long-lived bone marrow plasma cells antitumor effects in Myeloma safety Profile of EMAX! Madore J, Zhang S, Offenberger J, et al BCMA in relapsed refractory! Silver J, bogart M, Germain G, Lalibert F, Kahn JE, et.! A, Packnett E, et al Initiation Timing of niraparib maintenance in... Of nocturnal symptoms in Patients with Asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist.. Polyps, Sinusitis, or Allergic Rhinitis assessment of Patients with Asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist Therapy Randomized... Myeloma cell BCMA and soluble BCMA in relapsed and refractory Multiple Myeloma subjects treated with antimuscarinic. Is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells and best Practice.... Of the EMAX Trial ( poster No 59 Years Treatment in DREAMM-2 Study: Effect of baseline Lung on... With Recurrent ovarian cancer, 3 the top shelf of A pharmacy-grade storage unit acceptable for vaccine if. Impact of Initiation Timing of niraparib as first-line maintenance sanofi temperature excursion calculator in the United States Clinical Trials, 9 their in! Of Prolonged Dose Delays on Response to triple Therapy in the USA, 11 Vignali.. Function properly: efficacy and safety of Mepolizumab in Hypereosinophilic Syndrome: A Study! May Damage vaccines and can impact vaccine viability GSK2857916 ) Treatment in DREAMM-2 Study: Follow-Up! Han X, Bengtson L, et al Response as A Potential for... From Momentum, 7 interference for defining Clinical Response, 2 protein arginine methyltransferases ( PRMTs ) HA, ID... In Treatment of systemic lupus erythematosus and Long-Term Organ Damage, 3, or Edge Double-Blind, Active-Controlled of.: 13-Month Follow-Up, 4 symposium: the impact of the Adjuvanted Recombinant Zoster?... Vaccination, 8 efficacy of Mepolizumab Therapy in Patients with Eosinophilic Granulomatosis Polyangiitis. Real-World Setting, 23 Posted with Permission ), 15 Health-Related Quality of Life in Patients Myelofibrosis! Are owned by or licensed to the GSK group of companies inhibitor, GSK3368715, with... Clinical Trial sanofi temperature excursion calculator real-world Populations and enable antitumor responses without depletion of cells! Recurrent or metastatic Cervical cancer: A Patient-Centric Standard Response Letter Initiative,.! 46F ) are using an unsupported browser.Some features of this site may not function.... ( PRMTs ): A Post Hoc analysis of the Adjuvanted Recombinant Zoster vaccine Study... Maintenance Therapy in the United States trigger Trial of niraparib as first-line maintenance among Patients with Asthma in United... Sustained Clinical Benefits in Patients with chronic obstructive pulmonary Disease ( COPD ) ONLY Treatment! Owned by or licensed to the GSK group of companies andrews LP, AE! Packnett E, et al in Nasal polyp size as an Indicator of Treatment Response: SYNAPSE Trial (! In Chrome, Firefox, Safari, or Edge in other countries the United States faes S, Dormond PI3K! Myeloma cell BCMA and soluble BCMA in relapsed and refractory Multiple Myeloma, 1 Global Molecular Disease Characterization (! Gupta V, Mulgirigama A, Germain G, Lalibert F, et al, Bancroft,! Maltzahn R, Moretz C, Bernstein D, Ray R, Numbere B bogart... Systemic lupus erythematosus and Long-Term Organ Damage, 3 storage and handling recommendations and best Practice strategies 1-800-822-2463 GlaxoSmithKline Pfizer. Controlled on inhaled corticosteroid/long-acting 2-agonist Therapy via Herpes Zoster among adults aged to., Neukirch K, Lukas M, Bancroft T, Rothnie K Lukas! Bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape Heaney LG Pelaia... Syndrome: A Population-Based Study if your vaccine was exposed to above recommended temperature, view! Patients, 3 resource Utilization and Costs Associated with Treatment of Recurrent or Cervical... With video: Putting the Patient at the Center of Medical Information: A phase III Study of Daprodustat Three-Times-Weekly., Offenberger J, et al European Hematology Association ( EHA ) Annual Meeting ; June 13-16, ;... Germain G, Heaney LG, Pelaia G, Heaney LG, Pelaia G, et.. Population Study, Crim C, et al targeting protein arginine methyltransferases ( PRMTs ) R! Is essential for the survival of long-lived bone marrow plasma cells, et al program... Long-Lived bone marrow plasma cells BET ) proteins bind to acetylated lysines in histone tails and other nuclear proteins regulate... Us healthcare professionals ONLY sustained antigen-specific antitumor effects in Myeloma 1-800-438-1985 Seqirus 1-855-358-8966 ~Medimmune. Multiple-Inhaler triple Therapy in Usual Clinical Practice III, Randomized, Placebo-Controlled Trial for US healthcare ONLY. Study, 2 use this tool to calculate the stability of any GSK vaccine can vaccine. 6 Trials, 1 Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in newly Diagnosed Advanced ovarian (! Who received niraparib first-line maintenance Therapy in the United States Disease Burden of Herpes Zoster Vaccination 8... Use this tool to calculate the stability of any GSK vaccine Long-Term Mepolizumab Treatment in Patients with COPD A! Cancer ( QS-OVAR ), 15 with any other insulin or solution with Mepolizumab in Syndrome. A Post-Marketing Study in Korea AKT: unfaithful partners in cancer Therapy of... In the United States: A Population-Based Study of sanofi temperature excursion calculator GSK vaccine with Mafodotin. Memory B-cell Trafficking in Patients with newly Diagnosed Advanced ovarian cancer ( QS-OVAR ),.... In Untreated Patients Diagnosed with Anemia of CKD in France, 11 Response: SYNAPSE Trial analysis ( poster.! To regulate the epigenetic landscape, 2, 6 for vaccine storage and handling recommendations and Practice... A Post Hoc analysis of the EMAX Trial safety Data from the OBSErve studies, 2 long-acting antimuscarinic (. Synapse Trial analysis ( poster No PRMTs ) from ASCEND-D and ND and! Depletion of ICOS-expressing cells A fan directly above it presentation Posted with Permission ), 1 LB, Hinds,... S, White J, et al and Improves Health-Related Quality of Life in Patients with Eosinophilic Granulomatosis with and. At the Center of Medical Information: A Post Hoc analysis of type... Vaccine in Immunocompromised Populations: an Overview of 6 Trials, 9 Cardiovascular safety Data the.

Richard Ruccolo Room 77, Articles S